drug · antibody drug conjugate
disitamab vedotin
Phase 2updated 3mo agoby $PFE PFIZER INC🔗 ChEMBL
Phase 2community read0 votes
Antibody drug conjugate drug with a maximum clinical stage of Phase 3 (across all indications), with 12 investigational indications.
targets
Receptor tyrosine-protein kinase erbB-2Tubulin
all catalysts(0)
nothing on the calendar yet
Trials studying disitamab vedotin
- phase2A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- phase2A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
- phase3Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
- phase2A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
- phase2Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
- phase2A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
- phase3A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
- phase2DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that